Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery (CRS) for Colorectal Cancer: Potential for Individualized Care, Review of Current Treatment Trends, Recent Advancements, and a Look into the Future
Autor: | Craig Follette, Tyler Mouw, Sean C. Liebscher, Mazin Al-Kasspooles |
---|---|
Rok vydání: | 2019 |
Předmět: |
Oncology
medicine.medical_specialty Hepatology business.industry Colorectal cancer Gastroenterology Psychological intervention Disease medicine.disease Colorectal surgery 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine Conventional PCI medicine Peritoneal Cancer Index 030211 gastroenterology & hepatology Hyperthermic intraperitoneal chemotherapy Cytoreductive surgery business |
Zdroj: | Current Colorectal Cancer Reports. 15:36-44 |
ISSN: | 1556-3804 1556-3790 |
DOI: | 10.1007/s11888-019-00427-1 |
Popis: | Peritoneal metastases (PM) secondary to colorectal cancer is associated with a poor prognosis. However, cytoreductive surgery with hyperthermia intraperitoneal chemotherapy (CRS/HIPEC) has risen to a more accepted roll in the treatment of peritoneal metastatic disease for various cancers; colorectal cancer is no exception. This review aims to discuss the recent updates and findings for treatment of peritoneal disease secondary to colorectal cancer, especially with respect to individualized patient factors that affect outcomes. There are many new studies showing the validity of cytoreductive surgery CRS/HIPEC in a select group of patients with PM. Many studies show that lower peritoneal cancer index score, use of various chemotherapeutic regimens, histology, preoperative health status, adequate nutrition, and other factors all benefit survival/treatment of this unique patient group. Current evidence supports an aggressive multidisciplinary approach to peritoneal disease secondary to colorectal cancer. Standardized treatment practice, highly selective patient criteria, low PCI score, and early recognition of patients at risk for PM show survival benefits and better outcomes for patients with a disease process that was once only treated with palliative interventions. |
Databáze: | OpenAIRE |
Externí odkaz: |